The European Hematology Association 2022 Hybrid Congress (EHA2022)
Vienna, Austria 09 June 2022 - 12 June 2022
Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL
A time-limited regimen of venetoclax plus obinutuzumab with or without ibrutinib improved progression-free survival (PFS) in fit, treatment-naïve patients with chronic lymphocytic leukaemia (CLL), according to results of the phase III GAIA/CLL13 trial presented at EHA 2022.
Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL
13 Jul 2022
Age the biggest risk factor for COVID-19 mortality in haematological cancer patients
A study conducted in England has shown that in patients with haematological malignancy, the risk of COVID-19–related mortality is greatly influenced by age.
Age the biggest risk factor for COVID-19 mortality in haematological cancer patients
07 Jul 2022
Post-transplant KRd a new SoC for MM?
In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).
Post-transplant KRd a new SoC for MM?
07 Jul 2022
Updated ASCEMBL results boost asciminib potential for CML
In the week-96 analysis of the phase III ASCEMBL trial, the first BCR::ABL1 STAMP* inhibitor asciminib sustained superiority over bosutinib for individuals with CML-CP** who have failed ≥2 lines of prior tyrosine kinase inhibitors (TKIs).